Structural Intervention

Category icon
JIM 2021: Live Cases from Rotterdam

Nicolas M Van Mieghem, Roberto Diletti

Category icon
First-in-Human Use of the Next-generation ProtEmbo Cerebral Embolic…

Dariusz Jagielak, Radoslaw Targonski, Dariusz Ciecwierz,

Category icon
Removal of the ProtEmbo from the Aortic Arch

Dariusz Jagielak, Radoslaw Targonski, Dariusz Ciecwierz

Category icon
Removal of the Pigtail Catheter

Dariusz Jagielak, Radoslaw Targonski, Dariusz Ciecwierz

Category icon
Removal of the Delivery System for the Second Transcatheter Heart Valve

Dariusz Jagielak, Radoslaw Targonski, Dariusz Ciecwierz

Category icon
Crossing of the Second Transcatheter Heart Valve System

Dariusz Jagielak, Radoslaw Targonski, Dariusz Ciecwierz

Category icon
Removal of the Delivery System for First THV

Dariusz Jagielak, Radoslaw Targonski, Dariusz Ciecwierz

Category icon
Expansion of the First THV System

Dariusz Jagielak, Radoslaw Targonski, Dariusz Ciecwierz

Category icon
Crossing of First THV System

Dariusz Jagielak, Radoslaw Targonski, Dariusz Ciecwierz

Category icon
Deployment of the ProtEmbo in the Aortic Arch

Dariusz Jagielak, Radoslaw Targonski, Dariusz Ciecwierz

Category icon
Torqueing of the ProtEmbo Device Tip for Correct Deployment

Dariusz Jagielak, Radoslaw Targonski, Dariusz Ciecwierz

About

Valve replacement surgery can be an effective, lifesaving treatment option for people with aortic or mitral valve diseases.

Aortic valve replacement is often required in older patients but the surgical risk is often extremely high. Transcatheter aortic valve implantation (TAVI) is an established therapy for intermediate and high surgical risk patients with symptomatic severe aortic valve stenosis.

Approximately 1.8% of the US population has mitral valve disease, and an estimated 106,000 surgeries per year are for the treatment of valvular heart disease. The durability of surgical mitral valve repairs and replacement are limited. There is a 25% rate of significant mitral regurgitation recurrence in surgical repairs at 2 years and a 44% rate of primary valvular failure at 15 years, leaving the patient with either symptomatic mitral regurgitation, stenosis or both.

Related Articles

Articles

Article icon
First-in-Human Use of the Next-generation ProtEmbo Cerebral Embolic…

Published: - Dariusz Jagielak, Radoslaw Targonski, Dariusz Ciecwierz,

Citation: Interventional Cardiology Review 2021;16(Suppl 1):1–4.

Corrigendum to: Management of Tricuspid Regurgitation

Published: - Maurizio Taramasso, Christelle Calen, Andrea Guidotti,

Citation: Interventional Cardiology Review 2020;15:e12.

Intraventricular Conduction Disturbances After TAVI

Published: - Shu-I Lin, Mizuki Miura, Ana Paula Tagliari,

Citation: Interventional Cardiology Review 2020;15:e11.

Management of Valvular Disease During Pregnancy

Published: - Chiara Fraccaro, Noemie Tence, Giulia Masiero,

Citation: Interventional Cardiology Review 2020;15:e10.